Complex tumor and immune microenvironment render pancreatic ductal adenocarcinoma (PDAC) resistant to immune checkpoint inhibitors (ICIs). Therefore, a strategy to convert the immune hostile into an immunopermissive tumor is required. Recent studies showed that intratumoral injection of Toll-like receptor 9 agonist IMO-2125 primes the adaptive immune response. Phase I and II trials with intratumoral IMO-2125 demonstrated its safety and antitumoral activity.
Carbone, Carmine;Piro, Geny;Delfino, Pietro;De Sanctis, Francesco;Ugel, Stefano;Corbo, Vincenzo;Cappello, Paola;Bria, Emilio;Scarpa, Aldo;Tortora, Giampaolo
File in questo prodotto:
Non ci sono file associati a questo prodotto.